The startup develops a brain diagnostic technology that utilizes virtual reality goggles to assess spatial navigation functions linked to dementia risk. By focusing on olfactory field responses, the technology enables earlier diagnosis of dementia in older adults, potentially allowing for preventive measures.
Funding
Funding not disclosed
Founders
Product
Problem
Early detection of Alzheimer's disease is challenging because the initial brain changes occur at the microscopic level, often decades before noticeable symptoms appear. Traditional cognitive tests and brain imaging techniques may not detect these subtle, early-stage changes, delaying timely intervention and preventive measures.
Solution
MIG provides a VR-based brain health assessment that focuses on spatial navigation, a cognitive function linked to the entorhinal cortex, the area first affected by Alzheimer's disease. The VR experience measures a user's path integration ability, which declines even before the onset of mild cognitive impairment (MCI). By identifying deficits in spatial navigation, the technology aims to detect the earliest signs of Alzheimer's, allowing for timely lifestyle interventions and medical monitoring. The test is non-invasive, safe, and can be administered in non-clinical settings, providing a cost-effective way to screen at-risk individuals.
Target Audience
The primary target audience includes individuals aged 40 and above who are concerned about their cognitive health, as well as medical institutions, health management companies, and local governments seeking to implement early Alzheimer's detection programs.
Features
- VR-based assessment of spatial navigation and path integration abilities
- Focus on the entorhinal cortex, the earliest affected brain region in Alzheimer's disease
- Detection of cognitive decline even before the MCI stage
- Non-invasive and safe testing procedure
- Short test duration (12-15 minutes)
- Objective and stable results
- Integration with medical institutions for follow-up processes